CTOs on the Move

ZestDentalSolutions

www.zestdent.com

 
ZEST Dental Solutions has been manufacturing overdenture implant attachment systems as a global leader and being one of the top dental implant manufacturers for over forty years.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zestdent.com
  • 2875, Loker Avenue East
    Carlsbad, CA USA 92010
  • Phone: 800.262.2310

Executives

Name Title Contact Details

Similar Companies

Infinity Pharmaceuticals Inc

Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.

Suvoda

Suvoda’s sole focus is to offer the industry’s leading SaaS solution for randomization and trial supply management. Suvoda’s Interactive Response Technology (IRT/IWRS) combines the flexibility of a custom solution with the speed of a configurable platform, offering 4-week deployment, reimagined reporting, and easy integration.

Vanta Bioscience

Vanta Bioscience is a West Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspen Laser

Aspen Laser Systems is redefining pain management and recovery with our high intensity, class IV laser therapy devices. With over 30 years of experience, Aspen Laser delivers quality products and long-lasting results for your patients.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.